1. Home
  2. XRTX vs GOVX Comparison

XRTX vs GOVX Comparison

Compare XRTX & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

N/A

Current Price

$2.19

Market Cap

4.3M

Sector

Health Care

ML Signal

N/A

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$1.32

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XRTX
GOVX
Founded
2011
2001
Country
Canada
United States
Employees
N/A
17
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
4.0M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
XRTX
GOVX
Price
$2.19
$1.32
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
13.4K
878.2K
Earning Date
05-15-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.12
52 Week High
$3.60
$4.40

Technical Indicators

Market Signals
Indicator
XRTX
GOVX
Relative Strength Index (RSI) 48.03 43.02
Support Level $2.03 $1.10
Resistance Level $2.40 $2.00
Average True Range (ATR) 0.15 0.17
MACD -0.00 -0.01
Stochastic Oscillator 44.71 42.86

Price Performance

Historical Comparison
XRTX
GOVX

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Share on Social Networks: